White-label polygenic risk scores, end-to-end kit fulfillment, and a developer-ready API. Your brand. Your members. Your data.
Trusted by researchers and platforms
The difference genetics makes
A common lipid panel can look only mildly abnormal. A coronary artery disease PRS can reveal when the same result sits on top of elevated inherited risk.
LDL cholesterol is elevated.
Recommend lifestyle review, repeat testing, and treatment decisions based on age, blood pressure, and calculated risk.
Borderline LDL sits on top of high inherited coronary risk.
Use the elevated PRS result to prioritize earlier prevention planning, provider review, and tighter cardiometabolic follow-up.
PSA alone can trigger watchful waiting or a repeat test. Genetics helps distinguish a routine abnormality from a higher-priority risk profile.
Above the reference range.
Repeat PSA, assess symptoms and medications, and consider urology referral depending on age and clinical context.
The same PSA result carries more urgency.
Use the elevated inherited risk to prioritize shared decision-making, earlier specialist review, and follow-up cadence.
Endometriosis affects 1 in 9 women and carries an average diagnostic delay of 7-11 years. Standard hormonal workups are structurally unable to detect it; normal labs are not the same as no risk.
Hormonal panel within reference ranges.
Estradiol, progesterone, and inflammatory markers are unremarkable. Painful cycle symptoms may be primary dysmenorrhea. Monitor and reassess.
Genetics surfaces an inherited predisposition that a normal hormone panel was structurally unable to detect.
Flag for earlier specialist referral and consider endometriosis as a priority rather than a late-stage conclusion, potentially years ahead of a standard diagnostic pathway.
The lab result is clearly low. Polygenic risk can show whether the member is genetically predisposed to lower baseline vitamin D levels.
Below the target range.
Recommend supplementation, more sunlight exposure where appropriate, and recheck after an intervention period.
Genetics suggests a structural baseline tendency that may make this look like a chronic predisposition rather than a seasonal dip.
Set expectations for maintenance dosing and monitoring instead of treating this as a one-time seasonal dip.
A member reporting poor sleep and afternoon energy crashes may be getting generic advice that ignores their biology. Chronotype PRS and caffeine metabolism status can together reveal what generic guidance missed.
Sleep hygiene may need attention.
Avoid screens before bed, maintain a consistent sleep schedule, limit caffeine after 2pm, and consider earlier wind-down routines.
Genetics explains why generic sleep hygiene may miss.
Earlier wind-down targets may work against natural rhythm. Caffeine after noon may also stay active into bedtime for this profile.
A wearable like WHOOP can measure that recovery is poor. Genetics may help explain why, and shift the recommendation from generic rest to more targeted support.
Recovery is below your baseline.
Prioritize sleep, reduce training load, and ensure adequate nutrition and hydration before your next high-intensity session.
Genetics helps explain what HRV is measuring.
This member may have a stronger inflammatory response to training load, making recovery nutrition, sleep, and pacing more important.
Labs can show that iron stores are elevated. Genetics can explain whether inherited iron overload should be part of the clinical workup.
Iron stores are elevated.
Recommend repeat ferritin, iron saturation, liver markers, and a review of inflammation, alcohol, supplements, and diet.
Elevated ferritin now has a plausible inherited driver.
Prioritize transferrin saturation, family history review, and provider follow-up for hereditary hemochromatosis.
The platform
A complete stack, from kit fulfillment to API delivery, purpose-built for health platform partners.
The technology
We are deliberately anchored to low-pass whole genome sequencing at 0.5x coverage, imputed to 70+ million variants, delivering genome-wide data at $50 per test. For polygenic conditions, PRS performance is equivalent to 30x. For many common monogenic traits, accuracy is comparable too. 30x is priced for research labs and clinical diagnostics. At $50, a genetic baseline becomes something every member can have.
| lpWGS (Gencove) | Array genotyping | 30x WGS | |
|---|---|---|---|
| Coverage | Entire genome, imputed to 70M+ variants | Pre-selected ~500k-2M sites only | Entire genome at high depth |
| PRS performance | Equivalent to 30x for polygenic conditions | Reduced, limited to array sites | Equivalent to lpWGS for polygenic conditions |
| Ancestry performance | Strong across diverse populations | Optimised for European ancestry | Strong across diverse populations |
| Future-proofing | New insights from existing data. No retesting. | Locked to chip design. May require retesting. | New insights computable. No retesting. |
| Price per member | ~$50 | ~$50-$100 | $699-$1,499+ |
| Clinically validated? | eMERGE framework: formal risk thresholds for 9 conditions | Varies; many lack formal clinical thresholds | CLIA lab ≠ clinical validation. Requires physician interpretation. |
| Best for | Consumer health platforms at scale | Ancestry and basic wellness traits | Research, rare variant detection, clinical diagnostics |
Note: 30x sequencing at a CLIA-accredited lab is not the same as a clinically validated test. Clinical validation requires the assay, pipeline, variant class, and interpretation workflow to be validated for the specific claim being made.
Enabling discovery
As your member base grows, genome-wide data enables your team to build insights no competitor can replicate, without ever asking a member to retest.
As your member base reaches GWAS scale, Gencove's bioinformatics team can help you run novel discovery and build polygenic scores tuned to your own population. Insights your competitors cannot replicate, built on genetics collected at sign-up.
When the science moves (a new GLP-1 pharmacogenomics paper, a new cancer PRS, a newly validated condition), your team can compute new insights from existing member data. The genome is permanent. The value compounds over time.
How it works
Two integration paths. One for new sequencing, one for members who already have genetic data.
Trigger a kit order with a single API call, and Gencove handles fulfillment and shipping. Or let members import existing 23andMe or Ancestry data.
One API call to orderOur CAP and CLIA accredited lab processes the sample at 0.5x coverage and imputes genome-wide data across 70+ million variants. You receive a webhook when results are ready.
Results in 3-4 weeksRetrieve a consumer-ready PRS report with one API call, or use the variant-level API to build your own experience on top of structured JSON data.
One API call for resultsResources
Technical and scientific resources to help your team evaluate, implement, and communicate genetics to members.
A technical comparison of lpWGS, array genotyping, and 30x WGS, covering PRS performance, ancestry, future-proofing, and price.
Request the white paperBased on a Nature paper published in April 2026: GLP1R variants associated with treatment response and side effect risk in 27,885 patients.
Request the case studyPricing
A platform fee covers access, support, and storage. Per-sample fees apply at the time of ordering.